Board of Directors
Pharmaero’s Board of Directors holds to the responsibility to determine and oversee the Company’s overall strategy as well as in contributing to developing the Company as a focused, sustainable, global pharmaceutical device company.
Mats Persson, Chairman of the Board & Senior Advisor, SHL Group
Mats has held various positions within SHL Group since joined as Marketing Director in 1996. He was appointed Managing Director of SHL Medical AB in 2001 and Executive Vice President Europe for SHL Group in 2007. Since 2000 Mats is one of the owners of SHL Group and member of the Global Management Board. He holds a Senior Advisor position at SHL since the beginning of 2018.
During the 1980’s and 1990’s Mats has held positions in global pharmaceutical companies such as Glaxo, Upjohn and Pharmacia & Upjohn within sales, marketing and clinical trials. Mats is Pharmaero’s Chairman of the Board since the Company was founded in 2009.
Carl-Åke Carlsson, Board Member & CEO and President of Xellia Pharmaceuticals
Carl-Åke has held various positions within Xellia, where he started in the finance function in 1988. In 1995 he was appointed Vice President Finance, Business Development and IT, and in January 2000 he took on the role as President Alpharma Human Pharmaceuticals Division. From 2003 to December 2004 he was President of the U.S. Branded Pharmaceuticals Division and was appointed President of the Alpharma API Division in 2005. Today Carl-Åke is Chief Executive Officer and President of Xellia.
Carl-Åke holds an MBA from Heriot-Watt Business School, United Kingdom and a Bachelor’s degree in Business Administration from Oslo Business School in Norway.
Aleksander Danilovski, Board Member & Chief Scientific Officer and Senior Vice President Global R&D and Regulatory Affairs of Xellia Pharmaceuticals
Dr. Danilovski is currently Chief Scientific Officer (CSO) and leads global R&D and regulatory affairs at Xellia Pharmaceuticals, a specialty pharmaceutical company focused entirely on anti-infective treatments against serious and life-threatening infections. His previous work experiences include serving as Head of European R&D for Barr Laboratories (USA), and Head of Vertical integration (API and FDF activities), as well as Member of the Management Board for PLIVA Pharmaceuticals (Croatia).
Dr. Danilovski has participated in and led development of several novel and patented specialty pharmaceutical products including development of more than 100 different drug substances ranging from traditional synthetic API’s, semisynthetic and fermentation based API’s to rDNA technology based biologics/biosimilars; and development of more than 200 different drug products ranging from solid-oral dosage forms (IR/SR, tablets and capsules, ODTs), parenterals (lyo and liquid), oral solutions, suspensions, emulsions and soft-gel capsules to semi-solids (ointments, creams and gels). He has authored more than 20 different patent families with granted patents and patent applications in various patent offices (USPTO, EPO, etc.)
Dr. Danilovski obtained his Ph.D. in Chemistry and Biochemistry from Cambridge University in the United Kingdom and University of Zagreb in Croatia, and his B.Sc. in Chemistry from the University of Zagreb in Croatia.